Tatiana Schlossberg’s Battle with Acute Myeloid Leukemia
Recently, Tatiana Schlossberg, who is 35 and the granddaughter of John F. Kennedy, shared that she has been diagnosed with terminal cancer. Specifically, she is dealing with acute myeloid leukemia (AML), and the situation has garnered attention following her announcement.
Schlossberg detailed her diagnosis in an essay that was published back in 2006. She discovered her illness after giving birth to her second child in May 2024. Unfortunately, one doctor informed her that she might only have about a year left to live.
The first clue to her condition emerged right after childbirth when doctors noticed an unusually high white blood cell count.
Understanding Acute Myeloid Leukemia
AML is a fast-moving type of leukemia that originates in the bone marrow—the soft interior of certain bones responsible for producing new blood cells. This form of cancer tends to spread quickly from the bone marrow to the bloodstream, and it can also impact various organs, including the lymph nodes, liver, brain, and even the testicles.
Dr. Steven Chan, an expert in leukemia, pointed out that Schlossberg’s type of AML is linked to a rare genetic mutation known as inversion 3, which is an abnormality affecting chromosome 3 in leukemia cells.
Symptoms and Risk Factors
The most common symptoms associated with this type of leukemia can include sudden fatigue, shortness of breath, unusual bleeding or bruising, and fever. Dr. Pamela Becker from City of Hope describes AML as resembling a severe flu that can leave individuals feeling unwell. Symptoms often lead to the discovery of abnormal blood counts during routine checks or when patients start feeling unwell.
It’s worth mentioning that known risk factors for AML can include previous chemotherapy, radiation exposure, smoking, and some genetic syndromes. However, many cases arise without a clear cause.
Treatment Options for AML
Treatment for AML usually revolves around intensive chemotherapy, often utilizing a combination of medications tailored to individual patient needs. For those with high-risk AML, chemotherapy may be followed by a stem cell transplant to reduce the chance of recurrence. This is a more complex process that usually entails a longer hospital stay and comes with a higher risk of side effects.
Unfortunately, there isn’t a specific treatment available yet for the unique chromosomal abnormality associated with Schlossberg’s illness, although several new therapies are under investigation.
For older patients who can’t handle intensive chemotherapy, a less intensive treatment option is available that allows for outpatient care. While this approach isn’t considered curative, patients have been known to maintain remission for months, even years.
Looking Ahead
Experts like Dr. Sikorski express hope regarding the future of AML treatments, suggesting that there has been more progress in the last decade than in the previous 30 years combined. New drugs specifically targeting various AML subtypes are now on the market, and innovative immune-based treatments are advancing into clinical trials.
As supportive care has improved over the years, patients are better able to endure treatments. Though targeted therapies for the inversion 3 mutation are still lacking, ongoing research continues to include patients with high-risk AML, broadening the treatment landscape.
